Автор книги: Ирина Бодэ
Жанр: Медицина, Наука и Образование
Возрастные ограничения: +16
сообщить о неприемлемом содержимом
Текущая страница: 12 (всего у книги 12 страниц)
97. Cerebrolysin | EVER Pharma. Available at: https://www.everpharma.com/portfolio/neurology/cerebrolysin/. (Accessed: 29th October 2018)
98. Vastag, B. Biotechnology: Crossing the barrier. Nature 466, 916–918 (2010).
99. Chen, N. et al. Cerebrolysin for vascular dementia. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD008900.pub2
100. Ziganshina, L. E., Abakumova, T. & Vernay, L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst. Rev. (2017). doi:10.1002/14651858.CD007026.pub5
101. Смирнова М. Д. & Агеев Ф. Т. Статины – старые мифы и новые факты. Регулярные выпуски ‘РМЖ’ 1421–1428 (2017).
102. Chasman, D. I. et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821–7 (2004).
103. Liao, J. K. Safety and efficacy of statins in Asians. Am. J. Cardiol. 99, 410–4 (2007).
104. Stroes, E. S. et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012–22 (2015).
105. Kashani, A. et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114, 2788–97 (2006).
106. Riaz, H. et al. Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. Am. J. Cardiol. 120, 774–781 (2017).
107. McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. Cochrane Database Syst. Rev. (2016). doi:10.1002/14651858.CD003160.pub3
108. O’Donoghue, M. et al. Lipoprotein-Associated Phospholipase A 2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy – Thrombolysis In Myocardial Infarction) Trial. Circulation 113, 1745–1752 (2006).
109. Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD004816.pub5
110. Silva, M. A., Swanson, A. C., Gandhi, P. J. & Tataronis, G. R. Statin-related adverse events: A meta-analysis. Clin. Ther. 28, 26–35 (2006).
111. Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J. & Francis, D. P. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur. J. Prev. Cardiol. 21, 464–474 (2014).
112. Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).
Правообладателям!
Это произведение, предположительно, находится в статусе 'public domain'. Если это не так и размещение материала нарушает чьи-либо права, то сообщите нам об этом.
